UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Annals of oncology, 2011-07, Vol.22 (7), p.1622-1627

2011

Volltextzugriff (PDF)

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

Annals of oncology, 2013-11, Vol.24 (11), p.2892-2897

2013

Volltextzugriff (PDF)

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

Annals of oncology, 2015-08, Vol.26 (8), p.1667-1677

2015

Volltextzugriff (PDF)

Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies

Annals of oncology, 2010-09, Vol.21 (9), p.1756-1764

2010

Volltextzugriff (PDF)

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

Leukemia, 2015-07, Vol.29 (7), p.1578-1586

2015

Volltextzugriff (PDF)

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

Journal of clinical oncology, 1999-01, Vol.17 (1), p.268-276

1999

Volltextzugriff (PDF)

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Annals of oncology, 2012-09, Vol.23 (9), p.2356-2362

2012

Volltextzugriff (PDF)

Erector spinae plane block vs. peri‐articular injection for pain control after arthroscopic shoulder surgery: a randomised controlled trial

Anaesthesia, 2022-03, Vol.77 (3), p.301-310

2022

Volltextzugriff (PDF)

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program

Journal of clinical oncology, 1998-08, Vol.16 (8), p.2825-2833

1998

Volltextzugriff (PDF)

A Phase 1b 2 trial of mapatumumab in patients with relapsed refractory non-Hodgkin's lymphoma

British journal of cancer, 2010-12, Vol.103 (12), p.1783-1787

2010

Volltextzugriff (PDF)

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Journal of clinical oncology, 2000-09, Vol.18 (17), p.3135-3143

2000

Volltextzugriff (PDF)

Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma

Journal of clinical oncology, 2005-02, Vol.23 (4), p.694-704

2005

Volltextzugriff (PDF)

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Annals of oncology, 2018-11, Vol.29 (11), p.2271-2271

2018

Volltextzugriff (PDF)

Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma

Journal of clinical oncology, 2001-01, Vol.19 (2), p.389-397

2001

Volltextzugriff (PDF)

CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma

Seminars in oncology, 1999-10, Vol.26 (5), p.88-96

CZUCZMAN, M. S

1999

Volltextzugriff (PDF)

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

Annals of oncology, 1998-09, Vol.9 (9), p.995-1001

1998

Volltextzugriff (PDF)

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

Annals of oncology, 2007-07, Vol.18 (7), p.1216-1223

2007

Volltextzugriff (PDF)

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

Annals of oncology, 1999-06, Vol.10 (6), p.655-661

1999

Volltextzugriff (PDF)

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Blood, 2016-03, Vol.127 (9), p.1128-1137

2016

Volltextzugriff (PDF)

Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients

Bone marrow transplantation (Basingstoke), 2003-08, Vol.32 (4), p.405-410

2003

Volltextzugriff (PDF)

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO

Hematological oncology, 2019-06, Vol.37 (S2), p.227-229

2019

Volltextzugriff (PDF)

AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

Hematological oncology, 2019-06, Vol.37 (S2), p.114-115

2019

Volltextzugriff (PDF)

Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

Clinical cancer research, 2005-08, Vol.11 (16), p.5984-5992

2005

Volltextzugriff (PDF)

Novel antibodies in the treatment of non-Hodgkin's lymphoma

Netherlands journal of medicine, 2009-09, Vol.67 (8), p.311-321

2009

Volltextzugriff (PDF)

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma

Bone marrow transplantation (Basingstoke), 2008-04, Vol.41 (7), p.613-619

2008

Volltextzugriff (PDF)

1 – 25 von 236

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(225)
Mit Volltextzugriff
(205)

Publikationsform

Sprache

Englisch
(236)

Erscheinungsjahr

n.n

Thema

Humans
(115)
Science & Technology
(112)
Life Sciences & Biomedicine
(111)
Oncology
(72)
Male
(62)
Female
(61)
Middle Aged
(58)
Biological And Medical Sciences
(57)
Medical Sciences
(57)
Adult
(54)
Rituximab
(49)
Aged
(46)
Hematology
(33)
Hematologic And Hematopoietic Diseases
(32)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(31)
Treatment Outcome
(29)
Antibodies, Monoclonal, Murine-Derived
(27)
Antineoplastic Agents - Therapeutic Use
(27)
Antibodies, Monoclonal - Therapeutic Use
(26)
Antineoplastic Agents
(25)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma

Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Erector spinae plane block vs. peri‐articular injection for pain control after arthroscopic shoulder surgery: a randomised controlled trial

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program

A Phase 1b 2 trial of mapatumumab in patients with relapsed refractory non-Hodgkin's lymphoma

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma

CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO

AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS

Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

Novel antibodies in the treatment of non-Hodgkin's lymphoma

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma

Suchergebnisse filtern